NCT00737893View on ClinicalTrials.gov

Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Prostate CancerErectile Dysfunction
Interventions
DRUG

Placebo

Saline injection (solution prepared by research pharmacy) subcutaneously given the day before surgery, day of surgery, and the day after surgery.

DRUG

Erythropoietin (EPO)

Erythropoietin (EPO)-induced Protein 29, Human; 20,000 units subcutaneously given the day before surgery, day of surgery, and the day after surgery.

Trial Locations (1)

21287

Johns Hopkins Hospital, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER

NCT00737893 - Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy | Biotech Hunter | Biotech Hunter